Patient Education Blog

Posts Tagged ‘Antidote’

NO FDA Approval Yet for Antidote for Xarelto, Eliquis and Savaysa

| Bleeding, Blood thinners (anticoagulants), Therapy | Comments Off on NO FDA Approval Yet for Antidote for Xarelto, Eliquis and Savaysa

Stephan Moll, MD writes… The FDA did NOT approve Andexanet (brand names: AndexXa in the US, IndexXa in Europe) in a decision on August 18th, 2016.  Andexanet is the drug in clinical trials as an antidote to reverse the blood thinning effect of Eliquis®, Savaysa®, Xarelto® and Lovenox® (= enoxaparin).  The FDA is said to have requested more information from the company (Portola) making Andexanet, specifically (a) additional information related to manufacturing of the drug, and (b) more data to support inclusion of Savaysa and Lovenox (enoxaparin)  in the label.  The FDA also wants to finalize its review of the company’s proposals for post-marketing data collection on the performance of the drug.

It needs to be seen when the company (Portola) submits the requested additional information and when a new decision from the FDA is then to be expected. My guess is that this will be sometime in 2017.

References

  1. Portola announcement from Aug 18, 2016: http://bit.ly/2c1wKaK
  2. Connolly SJ et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. NEJM 2016;Aug 30 [e-pub]
     (http://dx.doi.org/10.1056/NEJMoa1607887)

 

Disclosure:  I have consulted for Portola, Janssen, and Boehringer-Ingelheim.

Last updated: Aug 31st, 2016

Major Bleeding on the New Oral Blood Thinners: Update on Reversal Drugs

| Bleeding, Blood thinners (anticoagulants), Eliquis - Apixaban, Pradaxa - dabigatran, Savaysa - Edoxaban, Therapy, Xarelto - Rivaroxaban | Comments Off on Major Bleeding on the New Oral Blood Thinners: Update on Reversal Drugs

Stephan Moll, MD writes (on Nov 7th, 2014)… A publication this week in the New England Journal of Medicine reports on a new reversal agent (PER977 = Aripazine = ciraparantag) that may be effective against a number of different new oral anticoagulants [ref 1]. Read the rest of this entry »

Reversal Agent for Eliquis – Early Clinical Study Results

| Eliquis - Apixaban | Comments Off on Reversal Agent for Eliquis – Early Clinical Study Results

Stephan Moll, MD writes….

The pharmaceutical company Portola reported today (May 8th, 2013) on the findings of their human volunteer study of their blood thinner antidote PRT4445 (ClinicalTrials.gov Identifier: NCT01758432  – medical details of the study design are here, study NCT01758432.  This dug is in early development.  In the study, healthy volunteers who had taken the new oral blood thinner Eliquis (Apixaban) received the reversal agent.  The study showed a “rapid and sustained and dose-related reversal” of the blood thinning effect of Eliquis” and “no serious adverse events”. Read the rest of this entry »